The webinar will feature presentations from Key Opinion Leaders (KOL) Leslie Citrome, MD (New York Medical College) and Larry Ereshefsky, PharmD (Apex Innovative Sciences).

Dr. Citrome will provide a brief introduction on schizophrenia and major neuropsychiatric disorders with overlapping conditions that are treated with an antipsychotic drug and unmet medical needs. Dr. Ereshefsky will then discuss the pathobiology of schizophrenia, clinical pharmacology of approved antipsychotics, unmet needs and opportunities and challenges in clinical development of new antipsychotics.

Reviva’s Founder, President and CEO, Dr. Laxminarayan Bhat, will present data supporting the clinical development strategy for the ongoing Phase 3 evaluation of Reviva’s brilaroxazine (RP5063) in schizophrenia. Brilaroxazine is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms with the potential to treat schizophrenia and other neuropsychiatric conditions caused by dysfunctional serotonin and dopamine signaling.

A live question and answer session will follow.